Bluejay Diagnostics, Inc. (BJDX) Insider Trading Activity

NASDAQ$2.69+0.08 (3.07%)
Market Cap
$1.18M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
487 of 885
Rank in Industry
65 of 113

BJDX Insider Trading Activity

BJDX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
Sells
$0
0

Related Transactions

About Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Insider Activity of Bluejay Diagnostics, Inc.

Over the last 12 months, insiders at Bluejay Diagnostics, Inc. have bought $0 and sold $0 worth of Bluejay Diagnostics, Inc. stock.

On average, over the past 5 years, insiders at Bluejay Diagnostics, Inc. have bought $92,359 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 500 shares for transaction amount of $1,635 was made by Dey Indranil (President and CEO) on 2023‑12‑13.

List of Insider Buy and Sell Transactions, Bluejay Diagnostics, Inc.

2023-12-13PurchaseDey IndranilPresident and CEO
500
0.044%
$3.27
$1,635
-85.64%
2023-12-13PurchaseDey Svetlanadirector
500
0.0413%
$3.07
$1,535
-85.64%
2023-03-28PurchaseDey IndranilPresident and CEO
2,000
0.0105%
$0.44
$880
-49.65%
2023-03-27PurchaseDey IndranilPresident and CEO
8,000
0.0393%
$0.44
$3,520
-53.01%
2023-03-24PurchaseDey Svetlanadirector
10,000
0.0502%
$0.44
$4,400
-51.67%
2022-08-26PurchaseFisher Kenneth RChief Financial Officer
20,000
0.0992%
$1.03
$20,600
-57.23%
2022-04-25PurchaseFisher Kenneth RChief Financial Officer
20,000
0.0943%
$0.99
$19,800
-21.74%
2022-03-17PurchaseWurth Douglas Clark
40,000
0.1983%
$1.18
$47,120
-24.35%
2022-03-17PurchaseKinder Gordon WinstonChief Financial Officer
2,500
0.0122%
$1.16
$2,898
-24.35%
2022-03-17PurchaseDey Svetlana
10,000
0.0498%
$1.18
$11,830
-24.35%
2022-03-16PurchaseWurth Douglas Clark
60,000
0.2823%
$1.09
$65,400
-20.91%
2022-03-14PurchaseKinder Gordon WinstonChief Financial Officer
5,000
0.0274%
$1.02
$5,100
+1.69%
Total: 12

BJDX Institutional Investors: Active Positions

Increased Positions5+125%11,256+28.48%
Decreased Positions2-50%31,543-79.82%
New Positions3New10,710New
Sold Out Positions<1Sold Out14,942Sold Out
Total Postitions7+75%19,232-51.33%

BJDX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Drw Securities, Llc$39.002.99%59,767+59,767New2025-09-30
Sabby Management, Llc$19.001.48%29,628-66,405-69.15%2025-09-30
Tower Research Capital Llc (Trc)$3.000.22%4,448+2,176+95.78%2025-09-30
Bank Of America Corp /De/$0<0.01%12+7+140%2025-09-30
Ubs Group Ag$00%0-444Sold Out2025-09-30
Citigroup Inc$00%0-241Sold Out2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.